Skip to main content

Table 1 Patient characteristics and lung function at screening visit

From: Efficacy and safety of nasal high-flow oxygen in COPD patients

  STIT-1 STIT-2 STIT-1 + 2
Patient demographics
 Sample size (n) 50 27 77
 Sex (male/female) 42/8 15/12 57/20
 Age, years (mean ± SD) 67.2 ± 8.5 64.4 ± 8.2 66.2 ± 8.5
 FEV1 group: 30–50% (n) 31 7 38
 FEV1 group: < 30% (n) 19 20 39
Lung function
 pred. FEV1, % (mean ± SD) 34.5 ± 11.2 24.9 ± 9.2 31.0 ± 11.4
 LTOT, O2 L/min (mean ± SD) 2.2 ± 1.7 2.4 ± 1.4 2.2 ± 1.6
 PaO2, mmHg (mean ± SD) 51.0 ± 6.1 47.0 ± 5.6 49.6 ± 6.2
 PaCO2, mmHg (mean ± SD) 40.0 ± 4.1 49.1 ± 5.4 43.2 ± 6.3
 SpO2 (%) 91 ± 2 89 ± 3 91 ± 2
  1. FEV1: forced expiratory volume in 1 s; LTOT: long term oxygen therapy